A phase <scp>III</scp> randomized, multicentre, double blind, active controlled trial to compare the efficacy and safety of two different anagrelide formulations in patients with essential thrombocythaemia – the <scp>TEAM</scp>‐<scp>ET</scp> 2·0 trialHeinz Gisslinger, Christoph Klade, Elena Karyagina et al.|British Journal of Haematology|2019Cited by 6
Phase 3 trial team-ET in 106 high-risk Essential Thrombocythemia patients, demonstrating non-inferiority of anathromb, a novel, extended-release anagrelide formulation, to the licensed comparatorHeinz Gisslinger, Veronika Buxhofer‐Ausch, Atanas Radinoff et al.|Lithuanian University of Health Sciences|2016Cited by 0